薬物動態
Print ISSN : 0916-1139
新規去痰薬Sodium 5-(acetylamino)-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonate(KI-111)の体内動態(第4報):経ロ投与による吸収,排泄および腸内細菌による分解
佐藤 雅樹矢野 三郎小笠原 定則
著者情報
ジャーナル フリー

1991 年 6 巻 2 号 p. 237-242

詳細
抄録
The metabolic fate of 14C-labelled Sodium 5-(acetylamino)-3, 5-dideoxy-D-glycero-D-galacto-2-nonulosonate (KI-111) has been investigated following oral administration. KI-111 administrated orally was excreted in urine (6%), feces (30%) and expired air (62%) within 72 hours after administration. KI-111 was thought to be metabolized by intestinal flora to CO2, therefore an in vitro study was conducted to confirm that assumption. Intestinal content of rats was collected sterilely and incubated with 14C-labelled KI-111 under nitrogen atmosphere. Twenty percent of the added radioactivity was detected in the excreted 14C02.This result showed that KI-111 was metabolized by intestinal flora to CO2.
著者関連情報
© 日本薬物動態学会
前の記事 次の記事
feedback
Top